HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study

Trastuzumab is the only approved targeted drug for first-line treatment of human epidermal growth factor receptor 2–positive (HER2+) metastatic gastric cancer (mGC). However, not all patients respond and most eventually progress. The multicenter VARIANZ study aimed to investigate the background of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Haffner, Ivonne, Schierle, Katrin, Raimúndez, Elba, Geier, Birgitta, Maier, Dieter, Hasenauer, Jan, Luber, Birgit, Walch, Axel, Kolbe, Katharina, Riera Knorrenschild, Jorge, Kretzschmar, Albrecht, Rau, Beate, Fischer von Weikersthal, Ludwig, Ahlborn, Miriam, Siegler, Gabriele, Fuxius, Stefan, Decker, Thomas, Wittekind, Christian, Lordick, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099392/
https://www.ncbi.nlm.nih.gov/pubmed/33764808
http://dx.doi.org/10.1200/JCO.20.02761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099392/
https://www.ncbi.nlm.nih.gov/pubmed/33764808
http://dx.doi.org/10.1200/JCO.20.02761

Ejemplares similares